Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature
Felice Crocetto(University of Naples Federico II), Giuseppe Di Lorenzo(CTO Andrea Alesini), Matteo Ferro(European Institute of Oncology), Vincenzo Caputo(University of Naples Federico II), Carlo Buonerba(CTO Andrea Alesini), Vincenzo Cosimato, Francesco Trama(University of Perugia), Ciro Imbimbo(University of Naples Federico II), Savio Domenico Pandolfo(University of L'Aquila), Erika Di Zazzo(University of Molise), Luca Scafuri(CTO Andrea Alesini), Achille Aveta(University of Naples Federico II), Biagio Barone(University of Naples Federico II), Ferdinando Fusco(University of Naples Federico II)
Cited by 68
Related Papers
Sperm recovery and ICSI outcomes in men with non-obstructive azoospermia: a systematic review and meta-analysis
|Human Reproduction Update|2019|305
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
|International Journal of Molecular Sciences|2022|190
Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice
|Biomedicines|2023|161
Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study
|Journal of Clinical Medicine|2021|131
Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma
|Journal of Clinical Medicine|2023|129